M. Woolhouse, C. Waugh, M. R. Perry, and H. Nair, Global disease burden due to antibiotic resistance -state of the evidence, J Glob Health, vol.6, p.10306, 2016.

L. J. Shallcross, S. J. Howard, T. Fowler, and S. C. Davies, Tackling the threat of antimicrobial resistance: from policy to sustainable action, Philos Trans R Soc Lond B Biol Sci, vol.370, 2015.

L. B. Rice, Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE, J Infect Dis, vol.197, pp.1079-81, 2008.

U. Theuretzbacher, S. Gottwalt, and P. Beyer, Analysis of the clinical antibacterial and antituberculosis pipeline, Lancet Infect Dis, 2018.

A. C. Rios, C. G. Moutinho, and F. C. Pinto, Alternatives to overcoming bacterial resistances: state-of-the-art

, Microbiol Res, vol.191, pp.51-80, 2016.

Z. Charlop-powers, J. G. Owen, and B. V. Reddy, Global biogeographic sampling of bacterial secondary metabolism, Elife, vol.4, p.5048, 2015.

L. L. Ling, T. Schneider, and A. J. Peoples, A new antibiotic kills pathogens without detectable resistance, Nature, vol.517, pp.455-464, 2015.

B. M. Hover, S. H. Kim, and M. Katz, Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens, Nat Microbiol, vol.3, pp.415-437, 2018.

P. K. Mantravadi, K. A. Kalesh, R. Dobson, A. O. Hudson, and A. Parthasarathy, The quest for novel antimicrobial compounds: emerging trends in research, development, and technologies, Antibiotics (Basel), vol.8, p.8, 2019.

J. J. Banik and S. F. Brady, Recent application of metagenomic approaches toward the discovery of antimicrobials and other bioactive small molecules, Curr Opin Microbiol, vol.13, pp.603-612, 2010.

B. K. Okada and M. R. Seyedsayamdost, Antibiotic dialogues: induction of silent biosynthetic gene clusters by exogenous small molecules, FEMS Microbiol Rev, vol.41, pp.19-33, 2017.

J. Jampilek, Design and discovery of new antibacterial agents: advances, perspectives, challenges, Curr Med Chem, vol.25, pp.4972-5006, 2018.

K. Bush and P. A. Bradford, Beta-lactams and beta-lactamase inhibitors: an overview, Cold Spring Harb Perspect Med, vol.6, 2016.

R. Domalaon, T. Idowu, G. G. Zhanel, and F. Schweizer, Antibiotic hybrids: the next generation of agents and adjuvants against Gram-negative pathogens?, Clin Microbiol Rev, p.31, 2018.

A. Okano, N. A. Isley, and D. L. Boger, vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics, Proc Natl Acad Sci, vol.114, pp.5052-61, 2017.

E. J. Kwon, M. Skalak, and A. Bertucci, Porous silicon nanoparticle delivery of tandem peptide anti-infectives for the treatment of Pseudomonas aeruginosa lung infections, Adv Mater, vol.29, 2017.

G. R. Rudramurthy, M. K. Swamy, U. R. Sinniah, and A. Ghasemzadeh, Nanoparticles: alternatives against drugresistant pathogenic microbes, Molecules, vol.21, 2016.

P. Karmakar and V. Gaitonde, Promising recent strategies with potential clinical translational value to combat antibacterial resistant surge, Medicines (Basel), vol.6, p.21, 2019.

C. W. Stratton, Phages, fitness, virulence, and synergy: a novel approach for the therapy of infections caused by Pseudomonas aeruginosa, J Infect Dis, vol.215, pp.668-70, 2017.

S. T. Abedon, P. Garcia, P. Mullany, and R. Aminov, Phage therapy: past, present and future, Front Microbiol, vol.8, p.981, 2017.

F. L. Gordillo-altamirano and J. J. Barr, Phage therapy in the postantibiotic era, Clin Microbiol Rev, vol.32, pp.66-84, 2019.

V. A. Fischetti, Development of phage lysins as novel therapeutics: a historical perspective, Viruses, vol.10, 2018.

M. Schmelcher, D. M. Donovan, and M. J. Loessner, Bacteriophage endolysins as novel antimicrobials, Future Microbiol, vol.7, pp.1147-71, 2012.

H. Kashani, H. Schmelcher, M. Sabzalipoor, H. , S. Hosseini et al., Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies, Clin Microbiol Rev, p.31, 2018.

K. E. Atkins and S. Flasche, Vaccination to reduce antimicrobial resistance, Lancet Glob Health, vol.6, p.252, 2018.

M. Lipsitch and G. R. Siber, How Can vaccines contribute to solving the antimicrobial resistance problem?, MBio, vol.7, 2016.

M. Mutsch, W. Zhou, and P. Rhodes, Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland, N Engl J Med, vol.350, pp.896-903, 2004.

A. Digiandomenico and B. R. Sellman, Antibacterial monoclonal antibodies: the next generation?, Curr Opin Microbiol, vol.27, pp.78-85, 2015.

D. I. Kisiela, H. Avagyan, and D. Friend, Inhibition and reversal of microbial attachment by an antibody with parasteric activity against the FimH adhesin of uropathogenic E. coli, PLoS Pathog, vol.11, p.1004857, 2015.

M. H. Wilcox, D. N. Gerding, and I. R. Poxton, Bezlotoxumab for prevention of recurrent Clostridium difficile infection, N Engl J Med, vol.376, pp.305-322, 2017.

S. M. Lehar, T. Pillow, and M. Xu, Novel antibody-antibiotic conjugate eliminates intracellular S. aureus, Nature, vol.527, pp.323-331, 2015.
DOI : 10.1038/nature16057

R. E. Hancock, A. Nijnik, and D. J. Philpott, Modulating immunity as a therapy for bacterial infections, Nat Rev Microbiol, vol.10, pp.243-54, 2012.
DOI : 10.1038/nrmicro2745

J. Munguia and V. Nizet, Pharmacological targeting of the host-pathogen interaction: alternatives to classical antibiotics to combat drug-resistant superbugs, Trends Pharmacol Sci, vol.38, pp.473-88, 2017.

R. E. Hancock and H. G. Sahl, Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies, Nat Biotechnol, vol.24, pp.1551-1558, 2006.
DOI : 10.1038/nbt1267

M. D. Seo, H. S. Won, J. H. Kim, T. Mishig-ochir, and B. J. Lee, Antimicrobial peptides for therapeutic applications: a review, Molecules, vol.17, pp.12276-86, 2012.

M. G. Scott, E. Dullaghan, and N. Mookherjee, An anti-infective peptide that selectively modulates the innate immune response, Nat Biotechnol, vol.25, pp.465-72, 2007.

P. A. Roberts, R. M. Huebinger, E. Keen, A. M. Krachler, and S. Jabbari, Predictive modelling of a novel anti-adhesion therapy to combat bacterial colonisation of burn wounds, PLoS Comput Biol, vol.14, p.1006071, 2018.

S. V. Lynch and J. P. Wiener-kronish, Novel strategies to combat bacterial virulence, Curr Opin Crit Care, vol.14, pp.593-602, 2008.

D. Skurnik, C. Cywes-bentley, and G. B. Pier, The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG, Expert Rev Vaccines, vol.15, pp.1041-53, 2016.

M. Raffatellu, Learning from bacterial competition in the host to develop antimicrobials, Nat Med, vol.24, pp.1097-103, 2018.

E. Angelakis, V. Merhej, and D. Raoult, Related actions of probiotics and antibiotics on gut microbiota and weight modification, Lancet Infect Dis, vol.13, pp.889-99, 2013.

E. Van-nood, A. Vrieze, and M. Nieuwdorp, Duodenal infusion of donor feces for recurrent Clostridium difficile, N Engl J Med, vol.368, pp.407-422, 2013.

Y. Wang, H. Venter, and S. Ma, Efflux pump inhibitors: a novel approach to combat efflux-mediated drug resistance in bacteria, Curr Drug Targets, vol.17, pp.702-721, 2016.

J. D. Docquier and S. Mangani, An update on ?-lactamase inhibitor discovery and development, Drug Resist Updat, vol.36, pp.13-29, 2018.

D. Wong and D. Van-duin, Novel beta-lactamase inhibitors: unlocking their potential in therapy, Drugs, vol.77, pp.615-643, 2017.

L. J. Farrell, R. Lo, J. J. Wanford, A. Jenkins, A. Maxwell et al., Revitalizing the drug pipeline: AntibioticDB, an open access database to aid antibacterial research and development, J Antimicrob Chemother, vol.73, pp.2284-97, 2018.

E. Cabezon, F. De-la-cruz, and I. Arechaga, Conjugation Inhibitors and their potential use to prevent dissemination of antibiotic resistance genes in bacteria, Front Microbiol, vol.8, p.2329, 2017.

J. F. Kokai-kun, T. Roberts, and O. Coughlin, The oral ?-lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies, Antimicrob Agents Chemother, vol.61, pp.2197-2213, 2017.

J. De-gunzburg, A. Ducher, and C. Modess, Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: a proof of concept study in healthy subjects, J Clin Pharmacol, vol.55, pp.10-16, 2015.

A. Izadpanah and R. L. Gallo, Antimicrobial peptides, J Am Acad Dermatol, vol.52, pp.381-90, 2005.

V. L. Cavera, T. D. Arthur, D. Kashtanov, and M. L. Chikindas, Bacteriocins and their position in the next wave of conventional antibiotics, Int J Antimicrob Agents, vol.46, pp.494-501, 2015.

D. Pletzer, S. C. Mansour, and R. Hancock, Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens, PLoS Pathog, vol.14, p.1007084, 2018.

D. E. Kadouri, K. To, R. M. Shanks, and Y. Doi, Predatory bacteria: a potential ally against multidrug-resistant Gramnegative pathogens, PLoS One, vol.8, p.63397, 2013.

W. Mun, H. Kwon, H. Im, S. Y. Choi, A. K. Monnappa et al., Cyanide Production by Chromobacterium piscinae shields it from Bdellovibrio bacteriovorus HD100 predation, MBio, vol.8, 2017.

L. S. Waters and G. Storz, Regulatory RNAs in bacteria, Cell, vol.136, pp.615-643, 2009.

A. Eyraud, P. Tattevin, S. Chabelskaya, and B. Felden, A small RNA controls a protein regulator involved in antibiotic resistance in Staphylococcus aureus, Nucleic Acids Res, vol.42, pp.4892-905, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-00951043

S. Colameco and M. A. Elliot, Non-coding RNAs as antibiotic targets, Biochem Pharmacol, vol.133, pp.29-42, 2017.

A. C. Greene, CRISPR-based antibacterials: transforming bacterial defense into offense, Trends Biotechnol, vol.36, pp.127-157, 2018.

D. Bikard, C. W. Euler, and W. Jiang, Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials, Nat Biotechnol, vol.32, pp.1146-50, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01103559

E. Bettiol, J. D. Wetherington, N. Schmitt, S. Harbarth, and . Consortium, Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals, Antimicrob Agents Chemother, vol.59, pp.3695-3704, 2015.

V. L. Simpkin, M. J. Renwick, R. Kelly, and E. Mossialos, Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps, J Antibiot (Tokyo), vol.70, pp.1087-96, 2017.

, Update of antibacterial agents in clinical development, WHO, 2018.

G. H. Talbot, A. Jezek, and B. E. Murray, The infectious diseases society of America's 10 x '20 inititative (ten new systemic antibacterial agents FDA-approved by 2020): is 20 x '20 a possibility?, Clin Infect Dis, 2019.